Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Bonavida

Showing results (101-110 of 192) with videos related to

Pageof 20
Sort By:
Exploration of Targeted Anti-Tumor Therapy|May 19, 2023
Cancer resistance via the downregulation of the tumor suppressors <i>RKIP</i> and <i>PTEN</i> expressions: therapeutic implicationsMatthew Moghaddam, Silvia Vivarelli, Luca Falzone, et al.
International Journal of Molecular Sciences|August 27, 2021
YY1 Silencing Induces 5-Fluorouracil-Resistance and <i>BCL2L15</i> Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic RelevanceSilvia Vivarelli, Luca Falzone, Saverio Candido, et al.
Cancer Research|January 25, 2005
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosisAli R Jazirehi, Sara Huerta-Yepez, Genhong Cheng, et al.
Cancer Research|October 22, 2009
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitizationStavroula Baritaki, Kam Yeung, Michael Palladino, et al.
Critical Reviews in Oncogenesis|April 5, 2022
Regulation of the c-myc Oncogene by the Circadian Clock and OncogenesisWilliam Ung, Silvia Vivarelli, Luca Falzone, et al.
Antioxidants & Redox Signaling|July 19, 2023
Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products <i>via</i> the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic ImplicationsIndy Bui, Stavroula Baritaki, Massimo Libra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectivelyMario I Vega, Ali R Jazirehi, Sara Huerta-Yepez, et al.
Critical Reviews in Oncogenesis|February 9, 2026
Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic AnalysesMai P Ho, Evagelia Skouradaki, Etini Otumo, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|July 22, 2025
Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphomaMai P Ho, Evagelia Skouradaki, Stavroula Baritaki, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinomaApostolos Zaravinos, Peggy Kanellou, Stavroula Baritaki, et al.
Pageof 20

Showing results (101-110 of 192) with videos related to

Sort By:
Pageof 20
Exploration of Targeted Anti-Tumor Therapy|May 19, 2023
Cancer resistance via the downregulation of the tumor suppressors <i>RKIP</i> and <i>PTEN</i> expressions: therapeutic implicationsMatthew Moghaddam, Silvia Vivarelli, Luca Falzone, et al.
International Journal of Molecular Sciences|August 27, 2021
YY1 Silencing Induces 5-Fluorouracil-Resistance and <i>BCL2L15</i> Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic RelevanceSilvia Vivarelli, Luca Falzone, Saverio Candido, et al.
Cancer Research|January 25, 2005
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosisAli R Jazirehi, Sara Huerta-Yepez, Genhong Cheng, et al.
Cancer Research|October 22, 2009
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitizationStavroula Baritaki, Kam Yeung, Michael Palladino, et al.
Critical Reviews in Oncogenesis|April 5, 2022
Regulation of the c-myc Oncogene by the Circadian Clock and OncogenesisWilliam Ung, Silvia Vivarelli, Luca Falzone, et al.
Antioxidants & Redox Signaling|July 19, 2023
Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products <i>via</i> the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic ImplicationsIndy Bui, Stavroula Baritaki, Massimo Libra, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectivelyMario I Vega, Ali R Jazirehi, Sara Huerta-Yepez, et al.
Critical Reviews in Oncogenesis|February 9, 2026
Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic AnalysesMai P Ho, Evagelia Skouradaki, Etini Otumo, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|July 22, 2025
Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphomaMai P Ho, Evagelia Skouradaki, Stavroula Baritaki, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinomaApostolos Zaravinos, Peggy Kanellou, Stavroula Baritaki, et al.
Pageof 20